C12N 2320/30
Special therapeutic applications
C12N2320/30 (Special therapeutic applications) appears on 4,362 US grants and 9,043 published applications in this corpus.
Search patents in C12N- Granted patents
- 4,362
- Published applications
- 9,043
- Assignees
- 2,223
- Inventors
- 11,892
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 3 | 0 |
| 2000 | 2 | 0 |
| 2001 | 0 | 1 |
| 2002 | 1 | 3 |
| 2003 | 1 | 22 |
| 2004 | 1 | 39 |
| 2005 | 1 | 96 |
| 2006 | 5 | 79 |
| 2007 | 5 | 82 |
| 2008 | 4 | 97 |
| 2009 | 24 | 154 |
| 2010 | 49 | 194 |
| 2011 | 68 | 226 |
| 2012 | 104 | 298 |
| 2013 | 122 | 287 |
| 2014 | 207 | 408 |
| 2015 | 259 | 523 |
| 2016 | 336 | 731 |
| 2017 | 380 | 587 |
| 2018 | 397 | 527 |
| 2019 | 400 | 559 |
| 2020 | 329 | 554 |
| 2021 | 304 | 654 |
| 2022 | 322 | 718 |
| 2023 | 277 | 615 |
| 2024 | 276 | 650 |
| 2025 | 276 | 564 |
| 2026 | 207 | 375 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Chemically modified oligonucleotides targeting bromodomain containing protein 4 (BRD4) for immunotherapy6 Oct 2026US 12,753,407 B2Phio Pharmaceuticals Corp.
- Compositions and methods for reprogramming age-restricted non-neuronal cells29 Sep 2026US 12,747,438 B2The Regents of the University of California
- Nutritional composition comprising miR-312629 Sep 2026US 12,747,439 B2Societe des Produits Nestle S. A.
- Antisense oligonucleotides for the treatment of stargardt disease29 Sep 2026US 12,747,440 B2ProQR Therapeutics II B.V.
- RNAi constructs and methods for inhibiting LPA expression22 Sep 2026US 12,742,169 B2Amgen Inc.
- Adenine base editors with reduced off-target effects8 Oct 2026US 2026/0308561 A1President and Fellows of Harvard College
- Reducing intron retention8 Oct 2026US 2026/0308583 A1University of Southampton
- Modulating apolipoprotein (a) expression8 Oct 2026US 2026/0308584 A1Ionis Pharmaceuticals, Inc.
- Compositions and methods for regulating expression of atxn28 Oct 2026US 2026/0308591 A1Riboway Therapeutics, Inc.
- Precision immunosuppression as prevention and therapy for graft-versus-host disease8 Oct 2026US 2026/0308592 A1
Most cited
By later US patents
- Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains568US 8,993,233 B2Massachusetts Institute of Technology · 2015
- CRISPR-Cas component systems, methods and compositions for sequence manipulation560US 8,795,965 B2Massachusetts Institute of Technology · 2014
- CRISPR-Cas component systems, methods and compositions for sequence manipulation529US 8,871,445 B2Massachusetts Institute of Technology · 2014
- Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation489US 8,865,406 B2Massachusetts Institute of Technology · 2014
- Engineering of systems, methods and optimized guide compositions for sequence manipulation480US 8,906,616 B2Massachusetts Institute of Technology · 2014